Mezzion Pharma Co.Ltd (140410.KQ) stock: key figures, P/E, revenue and dividend
Health Care · Pharmaceuticals · South Korea · ISIN KR7140410002
Mezzion Pharma Co.Ltd financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 8.61 bn KRW | 7.91 bn KRW |
| Gross profit | 1.91 bn KRW | 1.45 bn KRW |
| Operating income | -14.30 bn KRW | -16.77 bn KRW |
| EBIT | -14.23 bn KRW | -37.27 bn KRW |
| Net income | -19.48 bn KRW | -34.93 bn KRW |
| Diluted EPS – continuing operations | -650.02 KRW | -1,149.27 KRW |
Full history since 2012, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Mezzion Pharma Co.Ltd
Mezzion Pharma Co.,Ltd. engages in the development, licensing, and commercialization of drugs for the treatment of vascular diseases. It is developing Udenafil, a PDE5 inhibitor to treat erectile dysfunction, benign prostatic hyperplasia, pulmonary arterial hypertension, overactive bladder, hepatic portal hypertension, and chronic obstructive pulmonary diseases. The company was formerly known as Dong-A Pharmtech Co., Ltd. and changed its name to Mezzion Pharma Co.,Ltd. in April 2013. Mezzion Pharma Co.,Ltd. was founded in 2002 and is based in Seoul, South Korea.
More stocks
- Beach Energy Ltd (BPT.AX)
- Esentia Energy Development SA (ESENTIAII.MX)
- SonoScape Medical Corp (300633.SZ)
- Lightspeed Commerce Inc (LSPD.TO)
- Guangdong Marubi Biotechnology Co (603983.SS)
- Vanchip (Tianjin) Technology Co. Ltd. A (688153.SS)
- Pacira BioSciences, Inc. (PCRX)
- Hongrun Construction Group Co Ltd (002062.SZ)
- PHIBRO ANIMAL HEALTH CORP (PAHC)
- Mayr-Melnhof Karton AG (MMK.VI)
- Huadian Ener-B (900937.SS)
- Pagaya Technologies Ltd. (PGY)
Not investment advice. All data without warranty, price as of 04.11.2026. Details in the risk notice.